The Global Health Body Sounds Concern Over Acute Shortage of Obesity Medications

Fewer than a tenth of patients that would benefit from weight-loss injections like Wegovy have access to them, warns the global health agency as it publishes its inaugural guidance on the drugs.

Given in excess of 1,000,000,000 people worldwide currently classified as obese, it is calling for broader and more equitable availability to these injectable treatments.

Based on estimates, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.

"The latest guidelines recognises that obesity is a lifelong illness that can be treated with comprehensive and continuous support," remarked WHO director-general Tedros Adhanom Ghebreyesus.

High costs, limited production capacity, and distribution challenges are key hurdles to universal access to the treatments that can aid individuals in losing considerable body mass, says the body.

Skinny Jab Supply Crisis

Even under the current best projected case, the manufacturing of such drugs might only reach around 100 million people – less than 10% of eligible patients, per the WHO.

The guideline calls on countries and companies to widen availability, via approaches like licensing agreements.

Exclusive production rights on the active ingredient – the core component of a leading brand – is scheduled to end in multiple countries in 2026.

The Way Obesity Jabs Work

GLP-1 drugs mimick a biological compound to slow digestion, curb appetite and enhance feelings of fullness so people reduce food intake.

Patients commonly see weight reduction within a few weeks of starting on the regular doses.

Studies indicates patients may regain a significant portion within a year of stopping the medication, when their normal appetite resume.

Being above a healthy weight raises your chance for experiencing medical conditions, including diabetes, heart disease, stroke, and certain cancers.

Obesity affects people in every country and was responsible for over three and a half million deaths worldwide in 2024, as per the WHO.